Automate Your Wheel Strategy on RVTY
With Tiblio's Option Bot, you can configure your own wheel strategy including RVTY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RVTY
- Rev/Share 25.227
- Book/Share 64.0412
- PB 1.5791
- Debt/Equity 0.4646
- CurrentRatio 1.6824
- ROIC 0.0282
- MktCap 11738419105.0
- FreeCF/Share 4.5003
- PFCF 23.0395
- PE 47.3749
- Debt/Assets 0.2768
- DivYield 0.0028
- ROE 0.0324
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | RVTY | BofA Securities | Buy | Neutral | -- | $110 | Dec. 15, 2025 |
| Initiation | RVTY | Goldman | -- | Neutral | -- | $105 | Dec. 9, 2025 |
| Initiation | RVTY | Guggenheim | -- | Neutral | -- | -- | Oct. 16, 2025 |
| Upgrade | RVTY | UBS | Neutral | Buy | -- | $115 | May 1, 2025 |
| Downgrade | RVTY | Bernstein | Outperform | Market Perform | -- | $130 | Jan. 10, 2025 |
| Upgrade | RVTY | BofA Securities | Neutral | Buy | -- | $138 | Dec. 13, 2024 |
| Upgrade | RVTY | Barclays | Equal Weight | Overweight | $125 | $140 | Oct. 15, 2024 |
| Initiation | RVTY | Wells Fargo | -- | Equal Weight | -- | $130 | Aug. 28, 2024 |
News
Revvity: Close To A Buy, Not Quite There
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Neutral
Diagnostics is driving Revvity, Inc. growth, especially outside China. Signals software a standout: high-teens growth, SaaS ARR +40%. China immunodiagnostics and NIH funding remain key drags.
Read More
Here's Why Revvity (RVTY) is a Strong Momentum Stock
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Revvity Analysts Boost Their Forecasts Following Better-Than-Expected Q4 Results
Published: February 03, 2026 by: Benzinga
Sentiment: Positive
Revvity Inc. (NYSE: RVTY) on Monday reported better-than-expected earnings for the fourth quarter.
Read More
Revvity, Inc. (RVTY) Q4 2025 Earnings Call Transcript
Published: February 02, 2026 by: Seeking Alpha
Sentiment: Neutral
Revvity, Inc. (RVTY) Q4 2025 Earnings Call Transcript
Read More
Revvity Stock Up as Q4 Earnings Beat, Revenues In Line With Estimates
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Positive
RVTY stock climbs after Q4 adjusted EPS of $1.70 top estimates with revenue improving 5.9% to $772.1 million.
Read More
Revvity (RVTY) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Revvity Sees Steady Growth On Rising Demand From Pharma/Biotech Customers
Published: February 02, 2026 by: Benzinga
Sentiment: Positive
Revvity Inc. (NYSE: RVTY) on Monday reported fourth quarter 2025 adjusted earnings of $1.70 per share, up 19.7% year over year, beating the consensus of $1.55.
Read More
Will Revvity Q4 Earnings Benefit From Early Signs of Demand Recovery?
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Positive
RVTY's Q4 results are likely to benefit from early demand recovery signs in Life Sciences, but China Diagnostics headwinds may limit earnings upside.
Read More
Curious about Revvity (RVTY) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Revvity (RVTY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Read More
Revvity (RVTY) Earnings Expected to Grow: Should You Buy?
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Positive
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Artisan Mid Cap Value Fund Q4 2025 Performance Discussion And Portfolio Activity
Published: January 21, 2026 by: Seeking Alpha
Sentiment: Positive
Online travel agency Expedia, our top overall contributor in Q4, drove performance in the consumer discretionary sector. Our top performers in the energy and financials sectors were NOV, a provider of oilfield equipment, technology and expertise, and First Citizens, a North Carolina-based bank. Our largest new purchase was Houston-headquartered Prosperity BancShares, the fifth-largest bank in Texas.
Read More
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Positive
Revvity's diagnostics strength and fast-growing Signals Software support long-term growth, even as macro pressures and weak funding linger.
Read More
Revvity, Inc. (RVTY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 13, 2026 by: Seeking Alpha
Sentiment: Neutral
Revvity, Inc. (RVTY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Revvity teams up with Eli Lilly to bring TuneLab AI models to Signals Xynthetica, aiming to unlock secure, federated drug discovery at scale.
Read More
Revvity Advances AI-Driven Scientific Discovery With Signals Xynthetica
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
RVTY unveils Signals Xynthetica, an AI-augmented design platform that links predictive models with real lab data to speed discovery.
Read More
Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Read More
Revvity (RVTY) Up 9.5% Since Last Earnings Report: Can It Continue?
Published: November 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?
Read More
Revvity, Inc. (RVTY) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Revvity, Inc. ( RVTY ) Jefferies London Healthcare Conference 2025 November 18, 2025 9:00 AM EST Company Participants Maxwell Krakowiak - Senior VP & CFO Prahlad Singh - CEO, President & Director Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Okay. Thank you.
Read More
Revvity, Inc. (RVTY) Q3 2025 Earnings Call Transcript
Published: October 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Revvity, Inc. (NYSE:RVTY ) Q3 2025 Earnings Call October 27, 2025 8:00 AM EDT Company Participants Stephen Willoughby - Senior VP of Investor Relations & Head of ESG Prahlad Singh - CEO, President & Director Maxwell Krakowiak - Senior VP & CFO Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Michael Ryskin - BofA Securities, Research Division Daniel Leonard - UBS Investment Bank, Research Division Tycho Peterson - Jefferies LLC, Research Division Douglas Schenkel - Wolfe Research, LLC Puneet Souda - Leerink Partners LLC, Research Division Daniel Arias - …
Read More
RVTY Q3 Earnings Beat, Sales In Line, '25 EPS View Raised
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Revvity beats on Q3 earnings and raises 2025 EPS view, as balanced segment performance offsets margin pressure.
Read More
Revvity (RVTY) Reports Q3 Earnings: What Key Metrics Have to Say
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Revvity (RVTY) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Revvity (RVTY) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Analysts Estimate Revvity (RVTY) to Report a Decline in Earnings: What to Look Out for
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Negative
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
RVTY Collaborates With Sanofi for Early Detection of Type 1 Diabetes
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Revvity partners with Sanofi to launch a scalable diagnostic test for early T1D detection, expanding its reach beyond rare diseases.
Read More
Revvity, Inc. (RVTY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Revvity, Inc. (NYSE:RVTY ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 8:00 AM EDT Company Participants Maxwell Krakowiak - Senior VP & CFO Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst All right. Good morning.
Read More
Revvity to Present at Upcoming Investor Conferences
Published: August 18, 2025 by: Business Wire
Sentiment: Neutral
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: 2025 Wells Fargo Healthcare Conference Wednesday, September 3, 2025 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer 2025 Baird Global Healthcare Conference Tuesday, September 9, 2025 2:35 p.m. ET – Steve Willoughby, senior vice president, investor relations & ESG Attendees will receive an update on the Company and its strategic p.
Read More
Revvity Q2: Headwinds From China And Customers, Buy On Weakness
Published: July 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Revvity, Inc.'s focus on high-growth markets like cell and gene therapies and precision medicine positions it for long-term expansion despite near-term challenges. The recent divestiture streamlines Revvity's portfolio, allowing greater investment in specialized diagnostics and software, which are expected to drive future growth. While facing weak academic/government demand and China headwinds, Revvity maintains a strong capital structure and margin expansion potential through cost optimization.
Read More
Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook
Published: July 28, 2025 by: Investopedia
Sentiment: Negative
Revvity (RVTY) was one of the worst-performing stocks in the S&P 500 Monday after the medical device maker said it anticipated a "meaningful pullback" in its immunodiagnostics business in China.
Read More
Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More
Published: July 28, 2025 by: Investopedia
Sentiment: Positive
U.S. equities were mhigher at midday after President Donald Trump and European Commission President Ursula von der Leyen announced a new trade agreement between the U.S. and the European Union. The Dow Jones Industrial Average, Nasdaq, and S&P 500 all rose.
Read More
About Revvity, Inc. (RVTY)
- IPO Date 1965-07-06
- Website https://www.perkinelmer.com
- Industry Medical - Diagnostics & Research
- CEO Prahlad R. Singh
- Employees 11000